[Potential antiviral therapeutics for 2019 Novel Coronavirus].
Identifieur interne : 000254 ( PubMed/Curation ); précédent : 000253; suivant : 000255[Potential antiviral therapeutics for 2019 Novel Coronavirus].
Auteurs : H. Li [République populaire de Chine] ; Y M Wang [République populaire de Chine] ; J Y Xu [République populaire de Chine] ; B. Cao [République populaire de Chine]Source :
- Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases [ 1001-0939 ] ; 2020.
Abstract
The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains - severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir / ritonavir, lopinavir / ritonavir combined with interferon-β, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials.
DOI: 10.3760/cma.j.issn.1001-0939.2020.0002
PubMed: 32023685
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000254
Links to Exploration step
pubmed:32023685Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Potential antiviral therapeutics for 2019 Novel Coronavirus].</title><author><name sortKey="Li, H" sort="Li, H" uniqKey="Li H" first="H" last="Li">H. Li</name><affiliation wicri:level="1"><nlm:affiliation>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020</wicri:regionArea></affiliation></author><author><name sortKey="Wang, Y M" sort="Wang, Y M" uniqKey="Wang Y" first="Y M" last="Wang">Y M Wang</name><affiliation wicri:level="1"><nlm:affiliation>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020</wicri:regionArea></affiliation></author><author><name sortKey="Xu, J Y" sort="Xu, J Y" uniqKey="Xu J" first="J Y" last="Xu">J Y Xu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Basic Medical Sciences, Tsinghua University School of Medicine, Beijing 100084, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Basic Medical Sciences, Tsinghua University School of Medicine, Beijing 100084</wicri:regionArea></affiliation></author><author><name sortKey="Cao, B" sort="Cao, B" uniqKey="Cao B" first="B" last="Cao">B. Cao</name><affiliation wicri:level="1"><nlm:affiliation>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32023685</idno><idno type="pmid">32023685</idno><idno type="doi">10.3760/cma.j.issn.1001-0939.2020.0002</idno><idno type="wicri:Area/PubMed/Corpus">000254</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000254</idno><idno type="wicri:Area/PubMed/Curation">000254</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000254</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Potential antiviral therapeutics for 2019 Novel Coronavirus].</title><author><name sortKey="Li, H" sort="Li, H" uniqKey="Li H" first="H" last="Li">H. Li</name><affiliation wicri:level="1"><nlm:affiliation>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020</wicri:regionArea></affiliation></author><author><name sortKey="Wang, Y M" sort="Wang, Y M" uniqKey="Wang Y" first="Y M" last="Wang">Y M Wang</name><affiliation wicri:level="1"><nlm:affiliation>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020</wicri:regionArea></affiliation></author><author><name sortKey="Xu, J Y" sort="Xu, J Y" uniqKey="Xu J" first="J Y" last="Xu">J Y Xu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Basic Medical Sciences, Tsinghua University School of Medicine, Beijing 100084, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Basic Medical Sciences, Tsinghua University School of Medicine, Beijing 100084</wicri:regionArea></affiliation></author><author><name sortKey="Cao, B" sort="Cao, B" uniqKey="Cao B" first="B" last="Cao">B. Cao</name><affiliation wicri:level="1"><nlm:affiliation>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020</wicri:regionArea></affiliation></author></analytic><series><title level="j">Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases</title><idno type="ISSN">1001-0939</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains - severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir / ritonavir, lopinavir / ritonavir combined with interferon-β, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32023685</PMID><DateRevised><Year>2020</Year><Month>02</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1001-0939</ISSN><JournalIssue CitedMedium="Print"><Volume>43</Volume><Issue>0</Issue><PubDate><Year>2020</Year><Month>Feb</Month><Day>05</Day></PubDate></JournalIssue><Title>Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases</Title><ISOAbbreviation>Zhonghua Jie He He Hu Xi Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Potential antiviral therapeutics for 2019 Novel Coronavirus].</ArticleTitle><Pagination><MedlinePgn>E002</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.issn.1001-0939.2020.0002</ELocationID><Abstract><AbstractText>The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains - severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir / ritonavir, lopinavir / ritonavir combined with interferon-β, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Y M</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>J Y</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Basic Medical Sciences, Tsinghua University School of Medicine, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Jie He He Hu Xi Za Zhi</MedlineTA><NlmUniqueID>8712226</NlmUniqueID><ISSNLinking>1001-0939</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="Publisher" Language="chi"><AbstractText>2019新型冠状病毒(2019-nCoV)是武汉不明原因肺炎的致病原。2019-nCoV在遗传学上与一种蝙蝠来源的新型冠状病毒比较接近，与SARS-CoV、MERS-CoV同为β属冠状病毒。目前临床上常用的抗病毒药物，包括神经氨酸酶抑制剂（奥司他韦、帕拉米韦、扎那米韦等）、更昔洛韦、阿昔洛韦、利巴韦林等药物对2019-nCoV均无效，不建议临床应用。目前研究证实可能有效的药物包括：瑞德西韦、洛匹那韦/利托那韦、洛匹那韦/利托那韦联合干扰素-β、恢复期血浆、单克隆抗体。但这些药物在2019-nCoV肺炎患者中的疗效和安全性有待进一步临床实验证实。.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">2019 novel coronavirus</Keyword><Keyword MajorTopicYN="N">Antiviral therapy</Keyword><Keyword MajorTopicYN="N">Infection</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32023685</ArticleId><ArticleId IdType="doi">10.3760/cma.j.issn.1001-0939.2020.0002</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000254 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000254 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:32023685
|texte= [Potential antiviral therapeutics for 2019 Novel Coronavirus].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:32023685" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |